Skip to main content

Table 1 Main features of the trials reported in ClinicalTrials.gov

From: Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar

ClinicalTrials.gov studies

All (752)

<  2008 (254)

2008–2015 (498)

 

N

%

N

%

N

%

Study phase

 0

3

0.4

3

0.6

 I

186

24.7

67

26.4

119

23.9

 I-II

54

7.2

21

8.3

33

6.6

 II

313

41.6

114

44.9

199

40.0

 II-III

6

0.8

2

0.8

4

0.8

 III

67

8.9

21

8.3

46

9.2

 IV

7

0.9

2

0.8

5

1.0

 Observational

71

9.4

18

7.1

53

10.6

 Missing

45

6.0

9

3.5

36

7.2

Center

 Multicenter

393

52.3

106

41.7

287

57.6

 Single-center

208

27.7

76

29.9

132

26.5

 Missing

151

20.1

72

28.4

79

15.9

Countrya

 America

489

65.0

195

76.8

294

59.0

 Europe

114

15.2

25

9.8

89

17.9

 International

99

13.1

17

6.7

82

16.5

 Asia

21

2.8

4

1.6

17

3.4

 Oceania

3

0.4

3

0.6

Study purposea

 Treatment

612

81.4

213

83.9

399

80.1

 Prevention and screening

20

2.7

6

2.4

14

2.8

 Diagnostic

15

2.0

2

0.8

13

2.6

 Supportive care

29

3.9

12

4.7

17

3.4

 Health services research

5

0.7

1

0.4

4

0.8

 Other

34

4.5

4

1.6

30

6.0

 Missing

37

5.0

16

6.3

21

4.2

Endpoint classification

 Efficacy

168

22.3

67

26.4

101

20.3

 Safety

80

10.6

27

10.6

53

10.6

 Safety and efficacy

256

34.0

68

26.8

188

37.8

 Other

106

14.1

18

7.1

88

17.7

 Missing

142

19.0

74

29.1

68

13.7

Sponsor

 Not-for-profit

463

61.6

189

74.4

274

55.0

 Profit

289

38.4

65

25.6

224

45.0

Study duration (years)

 Mean (SD)

4.48 (2.8)

 

4.12 (2.9)

 

4.64 (2.7)

 

 Range

1–24

 

1–24

 

1–21

 

Number of subjects

  < 50

382

51.6

142

37.2

240

62.8

  ≥ 50

359

48.5

105

29.3

254

70.8

  1. aSome discrepancies in the total are due to missing data; less than 5% of data are missing